Viatris Inc VTRS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Viatris Inc reported revenue across 17 products and services; the largest, Brands, was $9.18B (-0.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Brands$9.18Bshare n/a-0.2% yoy
- Generics$5.07Bshare n/a-7.8% yoy
- Lipitor$1.55Bshare n/a+5.5% yoy
- Norvasc$710Mshare n/a+5.4% yoy
- Lyrica$487Mshare n/a-1.7% yoy
- Epi Pen Auto Injectors$470Mshare n/a+19.8% yoy
- Viagra$408Mshare n/a+3.2% yoy
- Creon$366Mshare n/a+11.5% yoy
- +9 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$3.01B59.1%-12.5% yoy
- China$2.08B40.9%+8.8% yoy
Members sum to $5.09B against $14.3B consolidated (residual $9.16B) - eliminations or corporate lines the filer did not tag on this axis.
- Developed Markets Segment$2.03B57.6%+6.7% yoy
- Greater China Segment$680M19.3%+22.4% yoy
- Emerging Markets Segment$537M15.3%+2.7% yoy
- Japan Australia And New Zealand Segment$274M7.8%-1.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.